There are currently 2877 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
NCT06004336
Recruiting
To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Oligometastatic Renal Cell Carcinoma
Register for Updates
A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)
NCT06367972
Recruiting
To find out if local consolidation therapy (such as radiation therapy with or without other local therapies such as surgery, ablation \[the removal or destruction of a body part or tissue or its function\], or embolization \[a procedure that uses particles, such as tiny gelatin sponges or beads, to block a blood vessel\]) to all progressive sites of disease can help to control the disease compared with next-line systemic therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: OligoProgressive Metastatic Disease
Register for Updates
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533
Recruiting
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Research Site, Houston, Texas +2 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Phase I Study of HC-7366 for Acute Myeloid Leukemia
NCT06285890
Recruiting
To find a recommended dose of HC-7366 to patients with AML. The safety and effects of this drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia
Register for Updates
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163
Recruiting
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/25/2025
Locations: Prolato Clinical Research Center (PCRC), Houston, Texas +1 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women
NCT06409052
Recruiting
To learn more about women's attitudes toward and knowledge about endometrial cancer and options that might decrease the risk of developing
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Endometrial Cancer
Register for Updates
Prospective Evaluation of the Relation Between Different Questionnaires Measuring Radiation-induced Side-effect
NCT06295783
Recruiting
To learn more about how you would rate the intensity or severity of your symptoms during or after radiation therapy using questionnaires with different rating scales.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Radiation
Register for Updates
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
NCT05929612
Recruiting
To learn if response-adapted, ultra-low dose radiation therapy can help to control MZL. This means participates first receive lower does of radiation therapy and then, based on how the disease responds, may receive higher doses after that.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384
Recruiting
Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabiliz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: GSK Investigational Site, Houston, Texas
Conditions: Lung Diseases, Interstitial
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738
Recruiting
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Research Site, Houston, Texas
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
NCT06965413
Recruiting
The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus (DM). The study comprises of a 4-week screening period; a 48-week core treatment period, where all participants will receive tirzepatide as background treatment and will be randomized to one... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Juno Research, LLC, Houston, Texas
Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
Register for Updates
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT06859424
Recruiting
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination. Participants will: * Receive t... Read More
Gender:
ALL
Ages:
Between 18 years and 66 years
Trial Updated:
07/25/2025
Locations: MD Anderson, Houston, Texas
Conditions: AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Register for Updates